Conditions: Nasal Polyps
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 748
Healthy volunteers: no

Brief summary:
This study will evaluate the effectiveness and safety of MFNS in improving nasal congestion/obstruction and in reducing bilateral nasal polyps.

Detailed description:

Arms:
arm 1: Participants receive mometasone furoate nasal spray (MFNS) 200 mcg twice daily (BID) for 16 weeks arm 2: Participants receive matching placebo nasal spray BID for 16 weeks

Interventions: intervention 1: Mometasone Furoate Nasal Spray (MFNS) intervention 2: Placebo for MFNS
Intervention descriptions: intervention 1: MFNS, 200 mcg BID administered as two 50 mcg sprays in each nostril BID for up to 16 weeks intervention 2: Two sprays in each nostril BID for up to 16 weeks

Protocol document: